Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C14H27O2.C6H14N2.Pt |
Molecular Weight | 763.999 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Pt++].N[C@@H]1CCCC[C@H]1N.CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O
InChI
InChIKey=BGIHRZPJIYJKAZ-BLUNCNMSSA-L
InChI=1S/2C14H28O2.C6H14N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;/q;;;+2/p-2/t;;5-,6-;/m..1./s1
Miriplatin is a novel lipophilic platinum complex that was developed to treat hepatocellular carcinoma (HCC). Miriplatin hydrate was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Oct 16, 2009. It was developed and marketed as Miripla® by Dainippon Sumitomo Pharma on Jan 20, 2010 in Japan. Miriplatin hydrate is a lipophilic platinum complex that has high affinity to lipiodol. It is indicated for the treatment of transcatheter arterial chemoembolization of hepatocellular carcinoma. Miripla® is available as lyophilized powder for arterial injection, containing 70 mg of free Miriplatin. The recommended dose is 70 mg once daily.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
In vitro antitumor activity, intracellular accumulation, and DNA adduct formation of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum (II) suspended in lipiodol. | 2000 Jan |
|
Warming effect on miriplatin-lipiodol suspension for potential use as a chemotherapeutic agent for transarterial chemoembolization of hepatocellular carcinoma: In vitro study. | 2013 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ds-pharma.com/ir/news/pdf/ene20091016.pdf
70 mg of miriplatin is suspended in 3.5 mL of
suspension vehicle for this drug, and administered
once a day through catheter inserted into hepatic
artery.
Administration of miriplatin-suspension ends when
tumor vessel is filled with the drug, provided that
the upper limit should be 6 mL per administration
(equivalent to 120 mg of miriplatin). An observation
period of 4 weeks or longer is required in the case of
repeated administration.
Route of Administration:
Intra-arterial
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10744050
Miriplatin (SM-11355) suspended in Lipiodol (SM-11355/Lipiodol) showed cytotoxic activity against rat ascites hepatoma AH-109A cells in a dose-dependent manner. IC50 value following 7-day exposure was 22.3 ug/ml.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB34987
Created by
admin on Sat Dec 16 01:33:17 GMT 2023 , Edited by admin on Sat Dec 16 01:33:17 GMT 2023
|
PRIMARY | |||
|
100000128194
Created by
admin on Sat Dec 16 01:33:17 GMT 2023 , Edited by admin on Sat Dec 16 01:33:17 GMT 2023
|
PRIMARY | |||
|
141977-79-9
Created by
admin on Sat Dec 16 01:33:17 GMT 2023 , Edited by admin on Sat Dec 16 01:33:17 GMT 2023
|
PRIMARY | |||
|
9832045
Created by
admin on Sat Dec 16 01:33:17 GMT 2023 , Edited by admin on Sat Dec 16 01:33:17 GMT 2023
|
PRIMARY | |||
|
780F0P8N4I
Created by
admin on Sat Dec 16 01:33:17 GMT 2023 , Edited by admin on Sat Dec 16 01:33:17 GMT 2023
|
PRIMARY | |||
|
C167007
Created by
admin on Sat Dec 16 01:33:17 GMT 2023 , Edited by admin on Sat Dec 16 01:33:17 GMT 2023
|
PRIMARY | |||
|
m11894
Created by
admin on Sat Dec 16 01:33:17 GMT 2023 , Edited by admin on Sat Dec 16 01:33:17 GMT 2023
|
PRIMARY | |||
|
8131
Created by
admin on Sat Dec 16 01:33:17 GMT 2023 , Edited by admin on Sat Dec 16 01:33:17 GMT 2023
|
PRIMARY | |||
|
Miriplatin
Created by
admin on Sat Dec 16 01:33:17 GMT 2023 , Edited by admin on Sat Dec 16 01:33:17 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD